1. Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
- Author
-
Malvezi AD, Panis C, da Silva RV, de Freitas RC, Lovo-Martins MI, Tatakihara VL, Zanluqui NG, Neto EC, Goldenberg S, Bordignon J, Yamada-Ogatta SF, Martins-Pinge MC, Cecchini R, and Pinge-Filho P
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Aspirin pharmacology, Celecoxib, Cell Line, Cell Survival drug effects, Cells, Cultured, Enzyme-Linked Immunosorbent Assay, Immunity, Innate drug effects, Immunohistochemistry, Interleukin-1beta metabolism, Nitric Oxide metabolism, Pyrazoles pharmacology, Rats, Sulfonamides pharmacology, Transforming Growth Factor alpha metabolism, Transforming Growth Factor beta metabolism, Trypanosoma cruzi drug effects, Cyclooxygenase 1 metabolism, Cyclooxygenase 2 metabolism, Myoblasts, Cardiac parasitology, Trypanosoma cruzi immunology, Trypanosoma cruzi pathogenicity
- Abstract
The intracellular protozoan parasite Trypanosoma cruzi is the etiologic agent of Chagas disease, a serious disorder that affects millions of people in Latin America. Cell invasion by T. cruzi and its intracellular replication are essential to the parasite's life cycle and for the development of Chagas disease. Here, we present evidence suggesting the involvement of the host's cyclooxygenase (COX) enzymes during T. cruzi invasion. Pharmacological antagonists for COX-1 (aspirin) and COX-2 (celecoxib) caused marked inhibition of T. cruzi infection when rat cardiac cells were pretreated with these nonsteroidal anti-inflammatory drugs (NSAIDs) for 60 min at 37°C before inoculation. This inhibition was associated with an increase in the production of NO and interleukin-1β and decreased production of transforming growth factor β (TGF-β) by cells. Taken together, these results indicate that COX-1 more than COX-2 is involved in the regulation of anti-T. cruzi activity in cardiac cells, and they provide a better understanding of the influence of TGF-β-interfering therapies on the innate inflammatory response to T. cruzi infection and may represent a very pertinent target for new therapeutic treatments of Chagas disease., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF